Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWP16001 and DWC202518 Combination Therapy in Type 2 Diabetes Mellitus
NCT07619833Phase 3Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
A Phase 3 trial of enavogliflozin, metformin in type 2 diabetes mellitus (T2DM), sponsored by Daewoong Pharmaceutical. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
enavogliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07619833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619833.